• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

Biohaven Pharmaceuticals

Quote
  • cafead   Feb 01, 2020 at 01:46: PM
Because of the strong posting activity on this thread, we've created a separate discussion board for Biohaven. This thread is being moved to the new board. However, we strongly encourage you to start new message threads within the Biohaven board, rather than continuing to post just on this one thread. Creating new threads for different subjects on the board will make more usable for everyone.
 
Last edited:
























anonymous said:
Oh brother..discussing disease state is a blanket term to just going out there and probing the HCP's brain on why they do what they, do setting the table for when BH's product is ready to be sold. Yea be scared competition.
Click to expand...


I can on here because a friend of mine has been a rep here for maybe 3+ months and I’m about to take him for some doc introduction and wanted to learn more. I’ve never been a Pharma rep so I can’t prod ally relate, however as a neuro speciality surgical implant rep I can sell talking disease state all day long what is the issue?
 




anonymous said:
I can on here because a friend of mine has been a rep here for maybe 3+ months and I’m about to take him for some doc introduction and wanted to learn more. I’ve never been a Pharma rep so I can’t prod ally relate, however as a neuro speciality surgical implant rep I can sell talking disease state all day long what is the issue?
Click to expand...


My apologies for all the typos, I have a broken finger and I’m on my iPhone. I don’t see an “edit your post” button.
 












anonymous said:
Seems a little early to regret anything. What exactly are you regretting? We don't even have a product to sell yet.
Click to expand...

The specific numbers we are assigning to each prescriber on our lists guaranteeing how many times we are going to be calling on someone. Programming immediately after launch just to get them scheduled. Seems like there should be more strategy involved. Don’t get me wrong, the drug is going to be fun to sell.
 
















Totally chill out and just enjoy the ride! Fight for the business (like any other company) and may the best man win? Let go of the what if's. Allergan will win some, Lilly will win some and Biohaven will win some.
 
























Top Bottom
Back
Quote